Background:
Several lines of evidence suggest that the proliferation of ovarian carcinoma might be stimulated by gonadotrophins. a number of phase i/phase ii clinical trials have reported that the suppression of endogenous luteinizing hormone and follicle-stimulating hormone secretion by luteinizing hormone-releasing hormone (lhrh) analogs induced objective remissions and/or disease stabilization in 10-30% of patients with advanced refractory ovarian carcinoma. the current study was performed to evaluate whether the addition of lhrh agonist treatment to standard platinum-based chemotherapy could prolong survival of patients with surgically treated stage iii or iv epithelial ovarian carcinoma.
Methods:
One hundred and thirty-five patients with stage iii or iv epithelial ovarian carcinoma participated in this prospective randomized double blind trial. after cytoreductive surgery, 69 patients received monthly injections of a depot preparation of the lhrh agonist [d-trp6] lhrh (triptorelin, 3.75 mg) and 66 patients received placebo until their deaths or termination of trial, respectively. all patients were treated with a standard platinum-based chemotherapy, and, if necessary, with second- or third-line cytotoxic regimens.
Results:
Endogenous gonadotrophins were reliably suppressed in patients treated with triptorelin. however, their progression free and overall survival were not significantly different from that of patients receiving placebo injections (statistical power > 80% for a difference between both groups of > or = 20%).
Conclusions:
The results of this trial suggest that the suppression of endogenous gonadotrophins by conventional doses of an lhrh agonist produces no relevant beneficial effects in patients with advanced ovarian carcinoma who receive standard surgical cytoreduction and cytotoxic chemotherapy.